Key result
Mutation analysis in 7 patients with LGMD2B or Miyoshi myopathy identified 10 disease-causing variants of the dysferlin gene, including 4 novel pathogenic mutations.
Observational (n=7)
Mutational screening is necessary for specific diagnosis in primary dysferlinopathy patients because protein-based assays may yield false negative results due to dysferlin aggregation.
Mutational screening may aid specific diagnosis when protein assays are inconclusive; extends known dysferlin variants but leaves open validation in larger cohorts.
INTRODUCTION: Diagnosis of the limb-girdle muscular dystrophies (LGMDs) has been facilitated by the use of immunofluorescence microscopy, Western blot analysis, and rapid genetic testing. METHODS: We identified 7 patients with LGMD2B or Miyoshi myopathy (MM) phenotypes and performed detailed history, physical examination, and mutation analyses of genomic DNA. RESULTS: Ten disease-causing variants of the dysferlin gene (DYSF) were detected, 4 of which were novel and predicted to be pathogenic (IVS33+9G>T, c.1343T>C, c.4747T>G, and c.5066dupC). Two of these mutations (c.1343T>C and IVS33+9G>T) were associated with a reduction in sarcolemmal dysferlin expression, despite increased total mRNA and protein in mixed muscle homogenates, due to a pathological retention of the mutated polypeptide in the cytoplasm. CONCLUSIONS: Considering that protein-based assays may yield false negative test results and that dysferlin aggregation may be present in other LGMDs, mutational screening is necessary for specific diagnosis in primary dysferlinopathy patients exhibiting this phenotype.
No takes yet. Share an insight, caveat, or question.
Nilsson et al. (2012) conducted an observational in Limb-girdle muscular dystrophy type 2B (LGMD2B) or Miyoshi myopathy (MM) (n=7). Mutation analyses of genomic DNA was evaluated on Detection of disease-causing variants of the dysferlin gene (DYSF). Mutation analysis in 7 patients with LGMD2B or Miyoshi myopathy identified 10 disease-causing variants of the dysferlin gene, including 4 novel pathogenic mutations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: